Alvotech logo

AlvotechNASDAQ: ALVO

Profile

Sector:

Healthcare

Country:

Luxembourg

IPO:

16 June 2022

Next earnings report:

21 March 2025

Last dividends:

N/A

Next dividends:

N/A
$3.74 B
-20%vs. 3y high
87%vs. sector
-vs. 3y high
-vs. sector
-10.89
-293%vs. 3y high
3%vs. sector
-87%vs. 3y high
77%vs. sector

Price

regular market | Wed, 20 Nov 2024 14:30:00 GMT
$12.42-$0.08(-0.64%)

Dividend

No data over the past 3 years
$102.89 M$87.50 M
$102.89 M-$11.39 M

Analysts recommendations

Institutional Ownership

ALVO Latest News

Alvotech's Position In The Coming Biosimilar Gold Rush
seekingalpha.com21 November 2024 Sentiment: -

Alvotech focuses on biosimilars, aiming to lower healthcare costs amid rising drug prices and regulatory pressure against price hikes. Alvotech's aggressive market expansion shows promise with significant revenue growth and strategic product rollouts, despite a leveraged balance sheet. A diverse pipeline targeting high-value biologics and recent regulatory milestones position Alvotech for significant market impact in the biosimilar sector.

Alvotech (ALVO) Q3 2024 Earnings Call Transcript
seekingalpha.com14 November 2024 Sentiment: NEUTRAL

Alvotech (NASDAQ:ALVO ) Q3 2024 Earnings Conference Call November 14, 2024 8:00 AM ET Company Participants Benedikt Stefansson - Senior Director, Investor Relations and Global Communications Robert Wessman - Chairman and Chief Executive Officer Anil Okay - Chief Commercial Officer Joel Morales - Chief Financial Officer Ming Li - Chief Strategy Officer Conference Call Participants Balaji Prasad - Barclays Niall Alexander - Deutsche Bank Carl Byrnes - Northland Capital Markets Operator Good day, and thank you for standing by. Welcome to the Alvotech's Third Quarter 2024 Earnings Conference Call.

Alvotech Meeting Investors and Presenting at the Jefferies 2024 London Healthcare Conference on November 19–20, 2024
globenewswire.com25 October 2024 Sentiment: POSITIVE

REYKJAVIK, Iceland, Oct. 25, 2024 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, announced today its participation in the Jefferies London Healthcare Conference, November 19-20, 2024. Members of the management team will host one-on-one meetings on both days. Alvotech will be presenting at the conference on Tuesday, November 19, 2024 at 9:00-9:25 am GMT.

Alvotech and Teva Announce U.S. FDA Approval of Additional Presentation of SELARSDI™ (ustekinumab-aekn), Expanding its Label to Include Further Indications Approved for Reference Product, Stelara® (ustekinumab)
globenewswire.com22 October 2024 Sentiment: POSITIVE

Alvotech (NASDAQ: ALVO) and Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced that the U.S. Food and Drug Administration (FDA) has approved SELARSDI (ustekinumab-aekn) in a new presentation, 130 mg/26 mL (5 mg/mL) solution in a single-dose vial for intravenous infusion. This approval paves the way for SELARSDI to further align its label with the indications of the reference product Stelara® (ustekinumab) in the U.S. at launch, which is expected in the first quarter of 2025.

Alvotech Initiates Confirmatory Patient Study for AVT16, a Proposed Biosimilar to Entyvio®
globenewswire.com25 September 2024 Sentiment: POSITIVE

Alvotech (NASDAQ: ALVO), a global biotech company specialized in the development and manufacture of biosimilar medicines for patients worldwide, announced today the initiation of a confirmatory patient study for AVT16, a biosimilar candidate to Entyvio® (vedolizumab). The objective of the study is to demonstrate comparative efficacy, safety, and immunogenicity of AVT16 and Entyvio, in male and female participants 18-80 years old with moderate to severe active Ulcerative Colitis. Alvotech is one of two companies known to have initiated a global or multi-country confirmatory patient study for a biosimilar candidate to Entyvio.

Alvotech Initiates Confirmatory Patient Study for AVT16, a Proposed Biosimilar to Entyvio®
globenewswire.com25 September 2024 Sentiment: POSITIVE

REYKJAVIK, Iceland, Sept. 25, 2024 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO), a global biotech company specialized in the development and manufacture of biosimilar medicines for patients worldwide, announced today the initiation of a confirmatory patient study for AVT16, a biosimilar candidate to Entyvio® (vedolizumab). The objective of the study is to demonstrate comparative efficacy, safety, and immunogenicity of AVT16 and Entyvio, in male and female participants 18-80 years old with moderate to severe active Ulcerative Colitis. Alvotech is one of two companies known to have initiated a global or multi-country confirmatory patient study for a biosimilar candidate to Entyvio.

Alvotech to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference
globenewswire.com26 August 2024 Sentiment: POSITIVE

Alvotech (NASDAQ: ALVO), a global biotech company specialized in the development and manufacture of biosimilar medicines for patients worldwide, announces its participation in the Morgan Stanley 22nd Annual Global Healthcare Conference in New York.  Members of the management team will hold an in-person fireside chat on September 5, 2024, starting at 5:35 pm EDT (21:35 GMT).

Alvotech to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference
globenewswire.com26 August 2024 Sentiment: POSITIVE

REYKJAVIK, Iceland, Aug. 26, 2024 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO), a global biotech company specialized in the development and manufacture of biosimilar medicines for patients worldwide, announces its participation in the Morgan Stanley 22nd Annual Global Healthcare Conference in New York. Members of the management team will hold an in-person fireside chat on September 5, 2024, starting at 5:35 pm EDT (21:35 GMT).

Alvotech: Steady Progress Offers A Good Chance Of Upside
seekingalpha.com26 August 2024 Sentiment: POSITIVE

Alvotech offers exposure to the biosimilar industry at a cheaper price compared to other generic drug manufacturers. The company has successfully commercialized two biosimilar drugs - Stelara and Humira - with more in the pipeline. The company announced Q2 earnings on August 16th, with record revenues of $235.6 million and quarterly EBITDA of $102 million.

Alvotech Reports Record Revenues and Adjusted EBITDA for the Second Quarter and First Six Months of 2024
globenewswire.com15 August 2024 Sentiment: POSITIVE

Alvotech (NASDAQ: ALVO, or the “Company”), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today reported unaudited financial results for the first six months of 2024 and provided a summary of recent corporate highlights.

  • 1(current)
  • 2

What type of business is Alvotech?

Alvotech, through its subsidiaries, develops and manufactures biosimilar medicines for patients worldwide. It offers biosimilar products in the therapeutic areas of autoimmune, eye, and bone disorders, as well as cancer. The company's lead program is AVT02, a high concentration formulation biosimilar to Humira to treat various inflammatory conditions, including rheumatoid arthritis, psoriatic arthritis, Crohn's disease, ulcerative colitis, plaque psoriasis, and other indications; AVT04, a biosimilar to Stelara to treat various inflammatory conditions comprising psoriatic arthritis, Crohn's disease, ulcerative colitis, plaque psoriasis, and other indications; AVT06, a biosimilar to Eylea to treat various conditions, such as age-related macular degeneration, macular edema, and diabetic retinopathy; and AVT03, a biosimilar to Xgeva and Prolia, which is in the pre-clinical phase to treat prevent bone fracture, spinal cord compression, and the need for radiation or bone surgery in patients with certain types of cancer, as well as prevent bone loss and increase bone mass. In addition, it offers AVT05, a biosimilar to Simponi and Simponi Aria, which is in early phase development to treat various inflammatory conditions, including rheumatoid arthritis, psoriatic arthritis, ulcerative colitis, and other indications; AVT16, a biosimilar to an Entyvio product; AVT23, a biosimilar to Xolair, which is in late-stage development to treat nasal polyps; and AVT33, a biosimilar to an Keytruda product. Alvotech was founded in 2013 and is based in Luxembourg, Luxembourg.

What sector is Alvotech in?

Alvotech is in the Healthcare sector

What industry is Alvotech in?

Alvotech is in the Drug Manufacturers - Specialty & Generic industry

What country is Alvotech from?

Alvotech is headquartered in Luxembourg

When did Alvotech go public?

Alvotech initial public offering (IPO) was on 16 June 2022

What is Alvotech website?

https://www.alvotech.com

Is Alvotech in the S&P 500?

No, Alvotech is not included in the S&P 500 index

Is Alvotech in the NASDAQ 100?

No, Alvotech is not included in the NASDAQ 100 index

Is Alvotech in the Dow Jones?

No, Alvotech is not included in the Dow Jones index

When was Alvotech the previous earnings report?

No data

When does Alvotech earnings report?

The next expected earnings date for Alvotech is 21 March 2025